Meir Rigbi

Title: Meir Rigbi: Innovator in Anticoagulant Research

Introduction

Meir Rigbi is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of biochemistry, particularly in the development of anticoagulants. With a total of 6 patents to his name, Rigbi's work has had a notable impact on medical research and pharmaceutical applications.

Latest Patents

One of Rigbi's latest patents is focused on the production of a recombinant factor Xa inhibitor derived from the leech Hirudo. This invention provides a recombinant polypeptide with a specific amino acid sequence, which is crucial for its function. The method of producing this polypeptide involves transforming a host cell with an expression plasmid, culturing the cell, and recovering the polypeptide produced. Another significant patent involves a novel anticoagulant/modulator factor isolated from the saliva of the medicinal leech Hirudo medicinalis. This factor specifically inhibits bovine Xa factor without affecting bovine thrombin, showcasing its potential for therapeutic use.

Career Highlights

Throughout his career, Meir Rigbi has worked with notable organizations, including Yissum Research Development Company of the Hebrew University of Jerusalem and Biotechnology General Corporation. His research has contributed to advancements in anticoagulant therapies, making him a key figure in this specialized field.

Collaborations

Rigbi has collaborated with esteemed colleagues such as Craig M. Jackson and Miriam Orevi. These partnerships have further enhanced the scope and impact of his research endeavors.

Conclusion

Meir Rigbi's innovative work in the field of anticoagulants exemplifies the importance of research and development in medicine. His contributions continue to influence the landscape of pharmaceutical science, paving the way for future advancements.